Vital Signs Monitoring Devices Market

Future Market Insights suggests that within the vital signs monitoring devices landscape, the convergence of OTC FDA-cleared pulse oximetry, AI-enabled arrhythmia detection in home blood pressure monitors, and subscription-based remote monitoring platforms is shifting vital signs capture from episodic clinical encounters into continuous, ambient home-based surveillance. Analysts identify the FDA De Novo authorisation of OMRON's AI-enabled atrial fibrillation detection in home blood pressure monitors and the Philips-Masimo multi-year partnership expansion as the central pivot points for the industry, effectively creating a hospital-grade monitoring continuum that extends from the ICU to the patient's home.